Angiotensin (Ang) II plays an important role in regulating cardiovascular hemodynamics as well as cardiovascular structure.
The peptide angiotensin (Ang) II exerts a range of actions on the kidney, heart, vascular system, adrenal gland and central nervous system in physiological and pathophysiological states. Ang II also exerts long-term structural effects through its direct growth actions (1, 2) . Multiple lines of evidence have suggested the existence of Ang II receptor subtypes, but it was only recently that at least two distinct receptor subtypes were defined on the basis of their differential pharmacological and biochemical properties (3, 4). The major cardiovascular actions of Ang II are reported to be mediated by a seven membrane-spanning G-protein coupled receptor known as type 1 Ang II receptor or AT1 receptor (5, 6). In 1993, a second receptor subtype known as Ang II type 2 receptor or AT2 receptor was cloned (7, 8) . This cloning has provided us with further insights into the physiological roles of Ang II, and renewed the concept of Ang II actions on the pathogenesis of cardiovascular diseases and the consequent cardiovascular remodeling, as well as cardiovascular development. Table 1 summarizes the comparison of AT1 and AT2 receptors. The AT2 receptor is abundantly and widely expressed in fetal tissues, but present only at low levels in adult tissues such as adrenal gland, specific brain regions, uterine myometrium, heart and atretic ovarian follicles, and re-expressed in certain pathological conditions such as ovarian atresia, wound injury, myocardial infarction, and vascular injury (11-21), leading to the hypothesis that this receptor is involved in growth, development and/or differentiation. While both AT1 and AT2 receptors belong to the seven-transmembrane, G protein-coupled receptor family, recent evidence reveals that the functions of AT1 and AT2, receptors are antagonistic. AT1 receptors promote cell growth whereas AT2 receptors mediates growth inhibition (15, 17, (21) (22) (23) (24) (25) (26) (27) (28) , differentiation (29) (30) (31) and/or apoptosis (32) (33) (34) (35) (36) (37) (38) (39) (40) in vascular smooth muscle cells (VSMC), cardiomyocytes, endothelial cells, mesangial cells, neuronal cells (PC12W cell, a rat pheochromocytoma cell line) and fibroblasts (R3T3 cell) . Growth inhibitory effects of AT2 receptors are unique in that this is a seven-transmembrane, G protein-coupled receptor that counteracts the growth action of other receptors. In this review article, we will mainly focus on the signaling mechanism of AT2 receptors and discuss the molecular and cellular mechanism of this receptor's actions.
Cellular Effects of AT2 Receptor in Cardiovascular System
Growth Inhibition Stoll et al. (22) observed an antiproliferative influence of the AT2 receptor on cultured coronary endothelial cells. Goto et al. (27) reported that the cultured mesangial cells prepared from stroke-prone spontaneously hypertensive rats (SHRSP) showed lower expression of AT2 receptor and higher proliferation activity as compared to those of normotensive Wistar-Kyoto rats (WKY), suggesting that AT2 receptor may exert an antiproliferative effect in mesangial cells. Moreover, it has been reported that AT2 receptor stimulation in cultured rat neonatal cardiomyocytes and fibroblasts inhibited AT1 receptor dependent growth (17, 23, 28) . Consistent with these findings we also observed that AT2 receptor exerts antiproliferative effects on cultured rat adult VSMCs which were transfected with AT2 receptor (15, 24) . We also have demonstrated that the AT2 receptor mediates a developmentally regulated decrease in rat aortic DNA synthesis at the later stages of gestation. Using in vivo gene transfer of the AT2 receptor cDNA into injured rat carotid artery, we revealed that overexpression of the AT2 receptor transgene results in an attenuation of neointimal hyperplasia (15) . Ohkubo et al. (17) demonstrated that AT2 receptor is re-expressed in cardiac fibroblasts in fibrous regions in failing cardiomyopathic hamster hearts and that the increased AT2 receptor exerted an anti-AT1 receptor action on the progression of interstitial fibrosis during cardiac remodeling by inhibiting both fibrillar collagen metabolism and growth of cardiac fibroblasts.
Apoptosis
Programmed cell death (apoptosis) plays an important role in the development and remodeling of many structures. Data on the contribution of apoptosis to cardiovascular remodeling and the pathogenesis of cardiovascular diseases have been limited until recently, however, recent evidence suggests that the cellular composition of the heart and blood vessels are determined by a balance between apoptotic cell death, cell survival, cell proliferation and migration. We examined the effect of Ang II on apoptosis in VSMC and reported that AT1 receptor stimulation inhibited the onset of apoptosis induced by NO-donor, S-nitroso-1V acetylpenicillamine or sodium nitroprusside and serum growth factor removal in cultured VSMC (41) . In contrast to the effect of AT1 receptor, we demonstrated using AT2 receptor transfected VSMC that selective AT2 receptor stimulation enhances apoptosis after serum starvation (35) . We also observed the proapoptotic effects of AT2 receptor in PC12W cells (32) (33) (34) 40) and R3T3 cells (32, 33) . Dimmeler et al. (36) reported that selective antagonistic stimulation of the AT2 receptor also induced apoptosis in human umbilical venous endothelial cells. Moreover, Li et al. (38) demonstrated that Ang II induces apoptosis in the skin fibroblasts of the mouse embryo, but not in those prepared from AT2 receptor knockout mice. Consistent with these observations, we found in our preliminary experiments that AT1 receptor stimulation blocked apoptosis, and that AT2 receptor activation enhanced apoptosis in cultured neonatal rat cardiomyocytes (37) . In contrast, Anversa and his colleagues reported that Ang II induced apoptosis in cultured rat neonatal ventricular myocytes via a protein kinase C-mediated mechanism, an effect that was blocked by losartan (42) . Moreover, they postulated that p53 induced myocyte apoptosis via activation of the myocyte angiotensin system and that stretch-mediated release of Ang II in adult myocytes is coupled with apoptosis and the activation of p53 (43, 44) . The basis for this apparent discrepancy in our observation on AT1 vs. AT2 receptor effect on myocyte apoptosis is unclear. It may be partially dependent on the cell characteristics, and the conditions of the cell culture experiment. Further investigation to clarify this issue and its physiological relevance is clearly warranted.
Differentiation
Rat and mouse vascular AT2 receptors seem to be expressed at low levels in the aorta during early embryonic development, but at high levels during the later stages of development and in the neonate. AT2 receptor levels decline rapidly after birth (15, 31, 45, 46) , whereas the AT1 receptor in aorta is expressed at relatively constant levels. We have demonstrated that the expression of h-caldesmon and calponin is delayed in the aorta of the AT2 receptor null mouse, which suggests that the AT2 receptor enhances the differentiation of VSMCs (31) . Consistent with this finding, recent studies using neuronal cells suggest that AT2 receptor activation may enhance differentiation in NG108-15 cells (29) and in PC12W cells (30 (51) . A decrease in ERK activity in the heart of AT2 receptor transgenic mice has been shown (52), suggesting that the ERK inactivation by the AT2 receptor has a physiological role in vivo. Very recently, we observed that the fetal VSMCs prepared from AT2 receptor null mice exhibit a generalized exaggerated growth phenotype, and that ERK activity was higher in this VSMC at baseline and also in response to serum (46) . The difference in ERK phosphorylation between wild-type and AT2 receptor null mice was suppressed by vanadate but not by okadaic acid, suggesting that tyrosine phospha- tase is implicated in the difference in ERK activity. These findings suggest that AT2 receptor expression during fetal vasculogenesis influences the growth phenotype of VSMC via modulation of the ERK cascade. Taken together, these findings support the notion that the decreased activity in ERK via AT2 receptor stimulation is pivotal for AT2 receptor action in vivo. However, the substrates involved in the AT2 receptor-mediated cellular effects are not still known. We demonstrated in PC12W cells that nerve growth factor (NGF) activated Bcl-2 by ERKdependent phosphorylation, and that AT2 receptor inhibited NGF-mediated Bcl-2 phosphorylation by inhibiting ERK activity, thereby inducing apoptosis ( Fig. 1) (34) .
Given the breadth of its interaction with multiple growth factor receptors, we hypothesize that the AT2 receptor signaling must interact with other cellular signal transduction pathways in which tyrosine-phosphorylation is involved. It was shown that the stimulation of AT2 receptors in AT2 receptor cDNA transfected rat adult VSMC inhibited AT1 receptor-mediated tyrosine-phosphorylation of STAT (signal transducers and activators of transcription)1, STAT2 and STAT3 without influence on Janus kinase (Fig. 1) (53) . AT2 receptor activation also inhibited the tyrosine-phosphorylation of STAT1 induced by interferon-y, epidermal growth factor, and platelet derived growth factor. AT2 receptor also inhibited serine-phosphorylation of STAT1a and STAT3 via the inhibition of ERK activation. Taken together, these findings suggest that AT2 receptor can cross-talk negatively with multiple families of growth regulating receptors by inhibiting ERK and STAT activation.
Moreover, we observed that the AT2 receptor stimulation increased de novo ceramide production through PTPase activation (Fig. 2) (40) . Consistent with our findings Gallinat et al. (39) reported that AT2 receptor stimulation increased ceramide production without affecting sphingomyelin degradation, and induced apoptosis in PC12W cells. These results suggest that a variety of phosphatases are involved in AT2 receptor-mediated cellular events (Fig. 2) . However, specific phosphatases coupled with AT2 receptor have not been identified. It would be intriguing to find specific AT2 receptoractivated phosphatases. A reduction of MAP kinase phosphatase-1(MKP-1) has been reported in rat VSMC after vascular injury (54) and in the rat aorta in acute hypertension elicited by stress or vasoactive substances (55) , thus suggesting the important role of this enzyme in vascular remodeling and hypertension. Our finding in PC12W cells that pretreatment with antisense oligonucleotide of MKP-1 inhibited the proapoptotic effect of the AT2 receptor (32, 34) , suggests that MKP-1 is one of the AT2 receptor-activated phosphatases. In N1E-115 neuro- (50) . It is necessary to find the specific AT2 receptor-activated phosphatases and the substrates of these phosphatase involved in AT2 receptor-mediated differentiation, growth inhibition, and apoptosis. Concurrent activation of c-Jun N-terminal kinase (JNK) and inhibition of ERK activities are important for apoptosis in many cells. It has been reported that Ang II activates JNK in cultured cardiac myocytes through an increase in intracellular Ca2+ and activation of protein kinase C, and the activated JNK may regulate gene expression by activating AP-1 during Ang II-induced cardiac hypertrophy (56). Kim et al. (57) reported that the AT1 receptor mediated-activation of JNKs and ERKs may be responsible for balloon injury-induced rat neointima formation. Interestingly, we observed that AT2 receptor stimulation also increased JNK activity and induced apoptosis in cultured rat neonatal cardiomyocytes (37) . These findings suggest the important roles of JNK in Ang II mediated cellular events, although the mechanism and cellular effects of JNK activation via both AT1 and AT2 receptors are not well defined.
G Protein Coupling
Pertussis toxin treatment attenuated AT2 receptormediated ERK inactivation and resulted in inhibition of the growth inhibitory and proapoptotic effects of this receptor (24, 32) . Using co-immunoprecipitation studies with antibodies specific for various G protein a subunits, Zhang and Pratt (58) found that only antibodies specific for Gi a were able to co-immunoselect AT2 receptor binding sites in the membrane prepared from rat fetus. It has been demonstrated that transfection of the synthetic intracellular third loop peptide of the AT2 receptor into rat adult aortic VSMCs, resulted in ERK inactivation and growth inhibition, and that the 125I_ labeled third loop peptide of AT2 receptor was immunoprecipitated with anti-Gi a antibody (24) . Consistent with these observations, Sumners and his colleagues reported that the AT2 receptor stimulates potassium current in neurons cultured from rat hypothalamus and brain stem via a Gi protein coupling mechanism through the intracellular third loop of this receptor (59) . Moreover, Buisson et al. (49) demonstrated that in non differentiated NG108-15 cells, AT2 receptor stimulation decreased the Ttype calcium current amplitude, an effect that was reversed with GDPI9S and mimicked with GTPyS, and that the inhibitory effect of the AT2 receptor on the T-type Ca2+ current involves PTPase activity, thus supporting the notion that G proteincoupled-PTPase activation is involved in AT2 receptor signaling. Haithcock et al. (60) reported that the AT2 receptor signaling in renal proximal tubular cells involves G protein 8-and y-mediated phospholipase A2 activation. Taken together, these findings suggest that the AT2 receptor may be a G protein-coupled receptor and that the intracellular third loop domain of the AT2 receptor would be important for its signaling.
NO Production and Other Mechanisms
Siragy and Carey (61, 62) have demonstrated that activation of the renin-angiotensin system during sodium depletion increases renal nitric oxide production through stimulation by Ang II at the AT2 receptor and renal production of cyclic guanosine 3',5'-monophosphate (cGMP), and that AT2 receptor blockade potentiates AT1 receptor-induced prostaglandin E2 production (Fig. 2) . NO release by AT2 receptor stimulation was also reported in dog coronary microvessels and large coronary arteries (63) . Consistent with these results, Unger and his colleagues demonstrated that AT2 receptor-mediated cGMP production in hypertensive rat aorta is mediated by bradykinin and NO (64).
Madrid et al. (65) examined the effect of an AT1 or AT2 receptor antagonist on the impairment of the pressure diuresis and natriuresis response produced by NO synthesis blockade by N w-nitro-Larginine methyl ester (L-NAME). They observed that, in rats given L-NAME, valsartan elevated baseline excretory values at all renal perfusion pressures, but it had no effect on the sensitivity of the pressure diuresis and natriuresis response. However, the administration of PD-123319 to L-NAMEpretreated rats shifted the slopes of the pressure diuresis and natriuresis responses toward control values, indicating that the impairment produced by NO synthesis blockade on pressure diuresis is dependent on the activation of AT2 receptors. Carey and his research group demonstrated that Ang II mediates jejunal sodium and water absorption by an action on the AT2 receptor involving cGMP production, while Ang II inhibits absorption via the AT1 receptor (66) . Arima et al. (67) directly examined the AT2 receptor-mediated effect of Ang II on renal arterioles. They isolated and microperfused the rabbit glomerular afferent arteriole (Af-Art), which is a vascular segment crucial to the control of glomerular hemodynamics, and examined whether the AT2 receptor is involved in vasodilation, and if so, by what mechanism. They showed that the AT2 receptor mediates vasodilation and that dilation was suppressed by either disrupting the endothelium or inhibiting the cytochrome P-450 pathway, which suggests that Af-Art activation of the AT2 receptor causes endothelium-dependent vasodilation via a cytochrome P-450 pathway, possibly by epoxyeicosatrienoic acids. (68) and therefore increased angiotensins may act preferably on AT2 receptor (Fig. 3) . On the other hand, cardioprotective effects of ACE inhibitors may be due to a blockade of the renin-angiotensin system and! or inhibition of kinin destruction (69, 70) . Other expected effects of ACE inhibitors may be due to the blockade of other Ang receptors, including Ang 1-7 receptors and AT4 receptors, whose functions and expression patterns in diseased states are not well defined. Further understanding of the renin angiotensin system may contribute to new therapeutic strategies for cardiovascular diseases and hypertension. 
